

Microbiology: Microbiome science needs a healthy dose of scepticism

William P. Hanage

20 August 2014

To guard against hype, those interpreting research on the body's microscopic communities should ask five questions, says William P. Hanage.

Subject terms: Microbiology Research management



Eye of Science/SPL

A scanning electron micrograph of bacteria in human faeces, in which 50% of species originate from the gut.

Explorations of how the microscopic communities that inhabit the human body might contribute to health or disease have moved from obscure to ubiquitous. Over the past five years, studies have linked our microbial settlers to conditions as diverse as autism, cancer and diabetes.

This excitement has infected the public imagination. 'We Are Our Bacteria', proclaimed one headline in *The New York Times*. Some scientists have asserted that antibiotics are causing a great 'extinction' of the microbiome, with dire consequences for human health¹. Companies offer personalized analysis of the microbial content of faecal samples, promising consumers enlightening information. Separate analyses from the same person can, however, vary considerably, even from the same stool sample. Faecal transplants have been proposed — some more sensible than others — for conditions ranging from diabetes to Alzheimer's disease. With how-to instructions proliferating online, desperate patients must be warned not to attempt these risky procedures on themselves.

Top picks from **nature** news

- Seals brought TB to Americas
- Icelandic volcano shakes ominously
- Neanderthals: Bone technique redrafts prehistory

Microbiomics risks being drowned in a tsunami of its own hype. Jonathan Eisen, a microbiologist and blogger at the University of California, Davis, bestows awards for “overselling the microbiome”; he finds no shortage of worthy candidates.

Previous 'omics' fields have faltered after murky work slowed progress². Technological advances that allowed researchers to catalogue proteins, metabolites, genetic variants and gene activity led to a spate of associations between molecular states and health conditions. But painstaking further work dampened early excitement. Most initial connections were found to be spurious or, at best, more complicated than originally believed.

The history of science is replete with examples of exciting new fields that promised a gold rush of medicines and health insights but required scepticism and years of slogging to deliver even partially. As such, the criteria for robust microbiome science are instructive for all researchers. As excitement over the microbiome has filtered beyond academic circles, the potential mischief wrought by misunderstanding encompasses journalists, funding bodies and the public.

Crucial questions

Here are five questions that anyone conducting or evaluating this research should ask to keep from getting carried away by hype.

Can experiments detect differences that matter? Profiling a microbiome could produce a catalogue at the level of phyla, species or genes. Much work relies on analysis of *16S rRNA*, an ancient gene that tolerates little variation and so is reliably found across the bacterial kingdom. But this allows only a coarse sorting. For example, microbiomes associated with obesity have been distinguished by different ratios of bacterial phyla, which encompass a staggering range of diversity. If this criterion were used to characterize animal communities, an aviary of 100 birds and 25 snails would be considered identical to an aquarium with 8 fish and 2 squid, because each has four times as many vertebrates as molluscs. Even within a single

species, strains often differ greatly in the genes they contain.

“Press officers must stop exaggerating results, and journalists must stop swallowing them whole.”

Modern technology now allows for finer distinctions: we can study more genes in a sample, an ability that may enable us to decipher 'metabolic networks' revealing the biochemical reactions that a microbiome can perform. This kind of analysis could identify gene combinations, potentially from multiple species across a microbial community, that affect health for good or ill. However, pinning an outcome to any particular entity is likely to be hard unless the networks are already well characterized.

To take a simple example from a single bacterial species, we could show that vaccination eliminated 30% of known pneumococcal strains in a human population — but only because we knew in advance to focus on the genes targeted by the vaccine³. Our ability to identify functional differences in closely related genes is rarely sophisticated enough to pull out important genes or networks if we do not know what to look for in the first place. Moreover, genomes are littered with clues both true and false, such as 'hypothetical proteins' and genes that are understood poorly or not at all, but could make for important differences in what metabolic networks do.

We need to be able to identify functional differences in closely related genes from sequence alone. Until then, we must remember that apparent similarities might cloak important differences.

Does the study show causation or just correlation? A separate question is raised when distinct microbiomes can be identified and associated with diseases or other conditions. Then we are left with the chestnut of causes and correlates. Sometimes, a particular microbiome found in association with disease will be merely a bystander⁴.

A 2012 article comparing the gut microbiomes of old people living in care homes with those of old people living in the community found distinct microbiomes that correlated with multiple scores of frailty⁵. After accounting for some potentially confounding factors, the authors proposed a causal relationship: diet altered the microbiome, which in turn altered health. This explanation fits the data, but the reverse causality — the potential for poor health to alter the gut microbiome — was not explored. Frailer people probably have less active immune systems and differences in digestion (such as the time required for food to pass through the stomach and intestines) — factors that could change the microbiome. This work is not the only example of this sort of confusion.

Related stories

- Microbiome therapy gains market traction
- Policy: How to regulate faecal transplants
- Microbiome sequencing offers hope for diagnostics

More related stories

What is the mechanism? All scientists are taught the catechism that correlation is not causation, but

correlation almost always implies some sort of causal relationship. We just don't know what it is. We must determine it with careful experiments.

In the past three or four years, studies have advanced from characterizing a broad community of mainly unculturable microbes to identifying functional elements, individual taxa or particular properties. We can now design experiments to precisely define actions of components of the microbiome⁶, for example by reconstituting communities but leaving out specific taxa, or by precisely measuring the biochemical activity of an experimental microbiome in an 'organ on a chip'⁷. A return to a reductionist approach is essential if we are to pinpoint both whether the microbiome affects human health, and exactly how it does so.

How much do experiments reflect reality? Even if the microbiome can have an experimental effect, it may not be an important cause of the symptoms seen in ill people.

Much work has addressed the role that gut flora have in obesity, and several studies have found associations between the gut microbiome and weight gain⁸. To assess whether this association was cause or consequence, researchers collected gut-microbiome samples from human twins (one obese, one not) and introduced the microbiota to mice. Mice previously colonized with an 'obese' microbiome lost weight when supplied with a 'lean microbiome', but only if also fed a normal or low-fat diet. Diet alone had little effect⁹. Although this elegantly controlled experiment suggests great potential for the microbiome and related therapies to affect health, it also shows the microbiome's limits: the effect was dependent on other factors, in this case diet.

Microbiome studies often rely on germ-free mice. These animals allow researchers to readily introduce an experimental microbiota. But they do not represent the animals' natural state and are typically unhealthy owing to the lack of a microbiome. So results may not predict responses in animals with flourishing microbiomes. Mice and their microbiomes are also adapted to a rather different niche from humans, so results may not be generalizable.

Could anything else explain the results? There are good reasons to think that bacteria influence us in a host of ways. But there are many other — possibly more important — influences, such as diet in the earlier example. Whenever a study links a microbiome to a disease, wise critics should ask whether other contributors to disease are considered, compared and reported.

The hype surrounding microbiome research is dangerous, for individuals who might make ill-informed decisions, and for the scientific enterprise, which needs to develop better experimental methods to generate hypotheses and evaluate conclusions. Funding agencies must not let their priorities be distorted by the buzz around the field, but look dispassionately at the data. Press officers must stop exaggerating results, and journalists must stop swallowing them whole. In pre-scientific times when something happened that people did not understand, they blamed it on spirits. We must resist the urge to transform our microbial passengers

into modern-day phantoms.

Nature **512**, 247–248 (21 August 2014) doi:10.1038/512247a

References

1. Blaser, M. J. *Missing Microbes: How the Overuse of Antibiotics is Fueling our Modern Plagues* (Henry Holt and Co., 2014).
Show context
2. Wilkins, M. R. *et al. Proteomics* **6**, 4–8 (2006).
Show context Article PubMed ISI ChemPort
3. Croucher, N. J. *et al. Nature Genet.* **45**, 656–663 (2013).
Show context Article PubMed ISI ChemPort
4. Shanahan, F. *Nutr. Rev.* **70** (suppl. 1), S31–S37 (2012).
Show context Article PubMed ISI
5. Claesson, M. J. *et al. Nature* **488**, 178–184 (2012).
Show context Article PubMed ISI ChemPort
6. Goodman, A. L. *et al. Proc. Natl Acad. Sci. USA* **108**, 6252–6257 (2011).
Show context Article PubMed ChemPort
7. Huh, D. *et al. Nature Protocols* **8**, 2135–2157 (2013).
Show context Article ISI ChemPort
8. Ley, R. E. *Curr. Opin. Gastroenterol.* **26**, 5–11 (2010).
Show context Article PubMed ISI
9. Ridaura, V. K. *et al. Science* **341**, 1241214 (2013).
Show context Article PubMed ChemPort

Related stories and links

From nature.com

- **Microbiome therapy gains market traction**
13 May 2014
- **Policy: How to regulate faecal transplants**
19 February 2014
- **Microbiome sequencing offers hope for diagnostics**
23 March 2012

- Gut microbial 'enterotypes' become less clear-cut

21 March 2012

Author information

Affiliations

William P. Hanage is associate professor of epidemiology at the Harvard School of Public Health in Boston, Massachusetts, USA.

Corresponding author

Correspondence to: William P. Hanage

For the best commenting experience, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will see comments updating in real-time and have the ability to recommend comments to other users.

2 comments

[Subscribe to comments](#)



Kenneth Witwer • 2014-08-21 02:19 AM

Another question: Where did the sequence(s) come from? When extremely sensitive techniques are used, even minute levels of contamination must be considered. As demonstrated by Charlson and colleagues (<http://www.ncbi.nlm.nih.gov/pubmed/21680950>), even "sterile" instruments and solutions may have detectable bacterial sequences.



Kevin Healey • 2014-08-21 01:07 AM

Yes, its true that microbiome science needs a healthy dose of scepticism. Just like every other branch of science, lets not lose sight of that.

See other News & Comment articles from *Nature*

Nature ISSN 0028-0836 EISSN 1476-4687

© 2014 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.

partner of AGORA, HINARI, OARE, INASP, CrossRef and COUNTER

